PURPOSE OF REVIEW: This article provides an overview of the clinical and pathologic features of multiple sclerosis (MS) relapses and reviews evidence-based approaches to their treatment. RECENT FINDINGS: Despite the increasing number and potency of MS treatments, relapses remain one of the more unpredictable and disconcerting disease aspects for many patients with MS, making their accurate recognition and treatment an essential component of good clinical care. The expanding range of relapse treatments now includes oral corticosteroids, comparable in efficacy to IV methylprednisolone at a fraction of the cost. While this development improves access to prompt treatment, it also underscores the importance of recognizing mimics of MS relapses to reduce corticosteroid overuse and its attendant risks. SUMMARY: Like MS itself, MS relapse remains primarily a clinical diagnosis. The treatment options for MS relapse include corticosteroids, adrenocorticotropic hormone (ACTH), plasma exchange, and rehabilitation, used singly or sequentially, with the goal of limiting the duration and impact of associated disability. Even when treated promptly and effectively, clinical or subclinical sequelae of MS relapses frequently remain.
PURPOSE OF REVIEW: This article provides an overview of the clinical and pathologic features of multiple sclerosis (MS) relapses and reviews evidence-based approaches to their treatment. RECENT FINDINGS: Despite the increasing number and potency of MS treatments, relapses remain one of the more unpredictable and disconcerting disease aspects for many patients with MS, making their accurate recognition and treatment an essential component of good clinical care. The expanding range of relapse treatments now includes oral corticosteroids, comparable in efficacy to IV methylprednisolone at a fraction of the cost. While this development improves access to prompt treatment, it also underscores the importance of recognizing mimics of MS relapses to reduce corticosteroid overuse and its attendant risks. SUMMARY: Like MS itself, MS relapse remains primarily a clinical diagnosis. The treatment options for MS relapse include corticosteroids, adrenocorticotropic hormone (ACTH), plasma exchange, and rehabilitation, used singly or sequentially, with the goal of limiting the duration and impact of associated disability. Even when treated promptly and effectively, clinical or subclinical sequelae of MS relapses frequently remain.
Authors: Andrew J Solomon; Georgina Arrambide; Wallace Brownlee; Anne H Cross; María I Gaitan; Fred D Lublin; Naila Makhani; Ellen M Mowry; Daniel S Reich; Àlex Rovira; Brian G Weinshenker; Jeffrey A Cohen Journal: Neurol Clin Pract Date: 2022-06
Authors: Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen Journal: Transfus Med Hemother Date: 2019-11-14 Impact factor: 3.747
Authors: Stephan Blechinger; Johannes Ehler; Gabriel Bsteh; Alexander Winkelmann; Fritz Leutmezer; Stefanie Meister; Agnes Santer; Michael Hecker; Thomas Berger; Paulus Rommer; Uwe Klaus Zettl Journal: Ther Adv Neurol Disord Date: 2021-01-27 Impact factor: 6.570
Authors: Saúl Reyes; Anthony L Cunningham; Tomas Kalincik; Eva Kubala Havrdová; Noriko Isobe; Julia Pakpoor; Laura Airas; Reem F Bunyan; Anneke van der Walt; Jiwon Oh; Joela Mathews; Farrah J Mateen; Gavin Giovannoni Journal: J Neuroimmunol Date: 2021-06-07 Impact factor: 3.478